Assuntos
Acetildigoxinas/administração & dosagem , Digoxina/análogos & derivados , Di-Hidroergotoxina/administração & dosagem , Transtornos Neurocognitivos/tratamento farmacológico , Acetildigoxinas/uso terapêutico , Idoso , Ensaios Clínicos como Assunto , Di-Hidroergotoxina/uso terapêutico , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Masculino , Distribuição AleatóriaRESUMO
1. Doses of clonidine 0.15 mg or guanfacine 1.0 mg, respectively, and 2 h later additional doses of clonidine 0.3 mg or guanfacine 2.0 mg, respectively, were given to 24 healthy students. 2. Blood pressure was reduced by the same amount by both drugs. 3. Plasma noradrenaline concentrations decreased with both drugs, but the reduction was significantly greater following the administration of clonidine. 4. Mental activity in the EEG was less suppressed in the guanfacine group than in the clonidine group. The differences were statistically significant. 5. Self-estimations for well-being and mood showed only small changes due to guanfacine but significant changes due to clonidine. 6. The decrease of information processing and the increase in reaction time, measured by performance in different psychometric tests, were significantly more pronounced after clonidine treatment than guanfacine. 7. A dose-response relationship could only be observed in vigilosomnograms, in the tests of self-estimation related to well-being and mood and in the decrease in plasma noradrenaline in the clonidine group. 8. It was concluded that guanfacine had a lesser CNS depressant action than clonidine, when administered in equipotent hypotensive doses.
Assuntos
Anti-Hipertensivos/farmacologia , Clonidina/farmacologia , Guanidinas/farmacologia , Processos Mentais/efeitos dos fármacos , Fenilacetatos/farmacologia , Adulto , Nível de Alerta/efeitos dos fármacos , Atenção/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Relação Dose-Resposta a Droga , Guanfacina , Humanos , Masculino , Motivação/efeitos dos fármacos , Norepinefrina/sangue , Psicometria , Tempo de Reação/efeitos dos fármacos , Autoavaliação (Psicologia)/efeitos dos fármacosRESUMO
A prospective study over 15 months in 100 elderly patients with signs of cerebro-vascular impairment demonstrated by psychometric testing that Hydergine (an ergot alkaloid preparation: 4.5 mg daily) compensated the signs of dementia, present in the placebo group, and in some patients actually brought about a significant improvement in mental activity. Similar compensatory effect was also demonstrable in cerebral haemodynamics: in the placebo group there was a progressive increase in cerebral circulation time, an expression of decreased cerebral blood flow, while with Hydergine cerebral circulation time was shortened and stabilized. Serial EEGs, obtained in parallel with psychometric and circulation time tests, demonstrated a marked increase in the 8-10 Hz pattern which corresponds to the physiological alpha activity in this age group. Furthermore, there was a diminished variability in performance in the tested frequency bands with Hydergine, the opposite tendency being obtained in the placebo group.
Assuntos
Transtornos Cerebrovasculares/tratamento farmacológico , Idoso , Circulação Cerebrovascular , Transtornos Cerebrovasculares/diagnóstico , Demência/diagnóstico , Demência/tratamento farmacológico , Demência/prevenção & controle , Di-Hidroergotoxina/administração & dosagem , Di-Hidroergotoxina/uso terapêutico , Método Duplo-Cego , Eletroencefalografia , Humanos , Placebos , Estudos Prospectivos , Testes Psicológicos , Fatores de TempoRESUMO
The efficacy of Hydergin was compared against placebo in a 15 weeks cross-over trial in 51 patients with cerebral insufficiency. The daily dosage was 3 mg of Hydergin. Criteria of evaluation consisted of clinical rating and electroencephalographic registrations, which were evaluated visually and partly automatically. The clinical symptoms as well as the electroencephalographic criteria (base line activity, theta- and delta activity) were both positively influenced by Hydergin. The base-line activity was stabilised and the alpha activity of the power spectrum increased. The most impressive result was the carryover effect of Hydergin, which could still be demonstrated in the post trial period. In case of "dizziness" the good results were limited to the period of active treatment. The relations between symptomatic and more basic therapy of cerebral insufficiency will be discussed.